← Back to patent-cliff list
利格列汀/盐酸二甲双胍
Tier B — Position earlyLinagliptin/Metformin Hydrochloride
Boehringer Ingelheim International Gmbh
Originator
2012
First approval
-
Expiry (public)
$1.86B ▲
Peak sales
化学药
Type
Targets：DPP4、PRKAB1
Brand：欧双宁、Trajenta Duo、Jentadueto、Jentadueto Xr
Indications (approved)：二型糖尿病
Regional status
US
批准上市
2012-01-30
EU
批准上市
2012-07-19
China
批准上市
2017-03-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Linagliptin/Metformin Hydrochloride?
Approved indications include: 二型糖尿病.
When does the Linagliptin/Metformin Hydrochloride patent expire?
No public expiry year is available for Linagliptin/Metformin Hydrochloride yet; this page updates once verified.
How do I get a quote for Linagliptin/Metformin Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24